

Safety Data Sheet for Drug Products (US)



Date of issue: 23-MAY-2017

Replaces version of:

GLEEVEC TAB 400MG 30

Section 1: Identification

Product name GLEEVEC TAB 400MG 30
Chemical Class Phenylamino-pyrimidine
Generic Name Imatinib mesylate
Pharmacological Action Tyrosine protein kinase inhibitor, Antitumour
Usage Drug product (pharmaceutical bulk, primary packed, finished product, pharmaceutical intermediate)
Company name Novartis Pharma AG
4002 Basel
Switzerland
Tel: +41 61 324 11 11, email: sds.support@novartis.com
Emergency phone number CHEMTEL (International) +1 813 676 1670 (365/24/7)

Section 2: Hazards identification

For side effects, which could also have impact for people working with this substance, please refer to the Patient Information Leaflet.

Section 3: Composition / information on ingredients

For classification of declared components, see section 15, "Regulatory Information"

Chemical Name	Contains:	CAS Number
Imatinib mesylate	60 - 62 %	220127-57-1

Remaining components are inert ingredients.

For TLV values of declared components, see Section 8, Exposure controls / Personal

Section 4: First aid measures

First aid measures for drug products

Inhalation Remove the victim from danger zone, avoid further exposure.
Skin Contact Remove contaminated clothing. Rinse contaminated skin immediately with plenty of water and soap and seek medical advice.
Eye Contact Immediately rinse eyes thoroughly with running water as long as possible (approx. 15 min). Take injured quickly to factory medical center or call an ambulance (code word: eye accident).
Ingestion If swallowed, seek medical advice immediately and show this container or label.
Notes to Physician General measures to eliminate the substance and to reduce absorption.

Section 5: Fire fighting measures

Suitable Extinguishing Media Water spray or fog, foam, dry chemical powder, CO₂, dry sand

Unsuitable Extinguishing Media No restrictions

Dangerous Combustion Products carbon oxides, nitrogen oxides, sulfur oxides

Protective equipment for firefighters Wear self-contained breathing apparatus and fire protective suite.

Section 6: Accidental release measures

Personal precautions Avoid contact with skin, eyes and clothing.

Safety Data Sheet for Drug Products (US)

Date of issue: 23-MAY-2017

Replaces version of:

GLEEVEC TAB 400MG 30

Environmental precautions Must not be released into sewers, drains or wells.

Methods for cleaning Transfer large quantities into a container. Clean up the rest with absorbent material and discharge properly.

Section 7: Handling and storage

No special handling requirements for normal use of this material.

Store in a dry and cool place and observe special instructions from supplier.

Section 8: Exposure controls / Personal protection

Occupational Exposure Limit (OEL)

no data available

TLV values of declared components

Contains:

Imatinib mesylate

List type	Value	Unit	
Internal exposure limit	84	µg/m ³	HHA Database

Personal protection for open handling

Health care personnel



Safety glasses (EN166) Lab coat Disposable gloves (EN374)

Section 9: Physical and chemical properties

Formulation Tablet

Flash Point not applicable

Section 10: Stability and reactivity

Under the normal conditions of use, the product is stable.

Section 11: Toxicological information

Acute Toxicity Data of Imatinib mesylate

LD50: 300 - 2000 mg/kg

Route: oral

Species: rat, Sex: female

Irritation, Corrosion

Data of Imatinib mesylate

Skin (Species: rabbit) non irritant

Sensitisation

Data of Imatinib mesylate

Skin (Species: guinea pig) not sensitizing

Mutagenicity

Data of Imatinib mesylate

Negative with and without metabolic activation (AMES-Test (reverse mutation assay))
in vitroCell: Strains of Salmonella typhimurium and Escherichia coli.

Data of Imatinib mesylate

Negative with and without metabolic activation (Gene Mutation Assay in Vitro)

in vitroCell: V79 cells (embryonic lung fibroblasts) of the Chinese hamster

Data of Imatinib mesylate

Negative (Micronucleus Test)

intravenous, Species: rat, Cell: Bone marrow

Chronic Effects

Data of Imatinib mesylate

Slight toxicity (Repeated Dose Toxicity)

Safety Data Sheet for Drug Products (US)



Date of issue: 23-MAY-2017

Replaces version of:

GLEEVEC TAB 400MG 30

NOAEL: 3 mg/kg/d
Route: oral
Species: dog, Organ: Multiple organs
Duration: 13 weeks
Data of Imatinib mesylate
Moderate Toxicity (Repeated Dose Toxicity)
NTEL: 5 mg/kg/d
Route: oral
Species: rat, Organ: Multiple organs
Duration: 26 weeks
Data of Imatinib mesylate
Moderate Toxicity (Repeated Dose Toxicity)
Route: oral
Species: dog, Organ: Liver
Duration: 34 weeks
Data of Imatinib mesylate
Testicular changes (Repeated Dose Toxicity)
Route: oral
Species: cynomolgus monkey (*Macaca fascicularis*), Organ: Male reproductive system
Duration: 39 weeks
Data of Imatinib mesylate
Carcinogen in animals (Carcinogenesis)
NOAEL: 15 mg/kg/d
Route: oral
Species: rat, Organ: Multiple organs
Duration: 104 weeks

Reproduction Toxicity

Data of Imatinib mesylate
Embryotoxicity at maternally toxic dose (Embryo-Fetal Development)
NOEL: 6 mg/kg/d
Route: oral
Species: rabbit, Sex: female
Data of Imatinib mesylate
Embryotoxicity/fetotoxicity and teratogenicity (Embryo-Fetal Development)
NOEL: 10 mg/kg/d
Route: oral
Species: rat, Sex: female
Data of Imatinib mesylate
Effect at high dose (Fertility and early Embryonic Development)
NOAEL: 20 mg/kg/d
Route: oral
Species: rat, Sex: both sexes
Data of Imatinib mesylate
Peri-Postnatal developmental effects (Peri- and Postnatal Development)
NOEL: 15 mg/kg/d
Route: oral
Species: rat, Sex: both sexes

Toxicological Hazard Classification

Acute Toxicity (oral): Data of Imatinib mesylate
Cat.4

Acute Toxicity (dermal): Data of Imatinib mesylate
not classifiable

Acute Toxicity (inhalation): Data of Imatinib mesylate
not classifiable

Eye Corrosion / Irritation: Data of Imatinib mesylate
not classifiable

Skin Corrosion / Data of Imatinib mesylate

Safety Data Sheet for Drug Products (US)



Date of issue: 23-MAY-2017

Replaces version of:

GLEEVEC TAB 400MG 30

Irritation:	not classified
Respiratory sensitizer	Data of Imatinib mesylate not classifiable
Skin sensitizer:	Data of Imatinib mesylate not classified
Germ cell mutation:	Data of Imatinib mesylate not classified
Carcinogenicity:	Data of Imatinib mesylate Cat.2
Reproductive toxicity:	Data of Imatinib mesylate Cat.2 dev.
Specific organ toxicity (single dose), not lethal:	Data of Imatinib mesylate not classifiable
Specific organ toxicity (repeated exposure):	Data of Imatinib mesylate Cat.2
Aspiration Hazard:	Data of Imatinib mesylate not applicable

Carcinogenicity listing

International Lists: Not Listed

Section 12: Ecological information

Fish acute toxicity	Data of Imatinib mesylate LC50: 82 mg/l Species: common carp (cyprinus carpio) Exp. time: 96 hours Method: OECD 203 * 1992 * acute toxicity
Fish chronic toxicity	Data of Imatinib mesylate NOEC: 10 mg/l LOEC: > 10 mg/l Species: fathead minnow (pimephales promelas) Exp. time: 30 days Method: OECD 210 * 1992
Aquatic invertebrate acute toxicity	Data of Imatinib mesylate EC50: 80 mg/l NOEC: 32 mg/l Species: daphnia magna (water flea) Exp. time: 48 hours Method: 92/69/EEC (L383) C.2 * Acute toxicity for daphnia
Aquatic invertebrate chronic toxicity	Data of Imatinib mesylate NOEC: 5.6 mg/l Species: daphnia magna (water flea) Exp. time: 21 days Method: OECD 211 * 2008
Algae Toxicity	Data of Imatinib mesylate ErC50: 6.8 mg/l ErC10: 2.1 mg/l NOEC: 0.96 mg/l Species: Pseudokirchneriella subcapitata/Selenastrum capricornutum (Green algae) Exp. time: 72 hours Method: 92/69/EC (L383) C.3
Bacterial Respiration Inhibition	Data of Imatinib mesylate EC10: 65 mg/l EC50: 232 mg/l EC80: 605 mg/l

Safety Data Sheet for Drug Products (US)



Date of issue: 23-MAY-2017

Replaces version of:

GLEEVEC TAB 400MG 30

	Species: activated sludge Exp. time: 3 hours Method: Inhibition of Oxygen Consumption by activated sludge (87/302/EEC), Part C
Toxicity to sediment-dwelling organisms	Data of Imatinib mesylate Species: Chironomus riparius Exp. time: 28 days Method: OECD TG No. 219 (2004)
Biological Elimination	Data of Imatinib mesylate Degradation: 9 - 12 % (aerobic: CO ₂) Not readily degradable Initial conc.: 19.5 mg/l, Duration: 28 days Method: 92/69/EC (L383) C.4-C * Carbon dioxide (CO ₂) evolution Inhibitory effects can be excluded.
Transformation in sediment-water systems	Data of Imatinib mesylate (Water) DT50: 0.25 - 2.3 days DT90: 4.3 - 10.4 days pH of compartment: 5.5 - 6.7 Duration: 100 days Method: OECD 308 * 2002* Aerobic and Anaerobic Transformation in Aquatic Sediment Systems Data of Imatinib mesylate (sediment) DT50: 131 - 137 days DT90: 434 - 454 days pH of compartment: 5 - 7.4 Duration: 100 days Method: OECD 308 * 2002* Aerobic and Anaerobic Transformation in Aquatic Sediment Systems Data of Imatinib mesylate (total system) DT50: 82 - 111 days DT90: 385 - 552 days Duration: 100 days Method: OECD 308 * 2002* Aerobic and Anaerobic Transformation in Aquatic Sediment Systems
Partition Coefficient	Data of Imatinib mesylate log Pow: 3.5 (Temperature: 37 °C) Method: OECD 117 * 1989
Biological accumulation	no data available
Soil and Sludge Sorption/Desorption	Data of Imatinib mesylate immobile (sludge) Koc: 4200 - 6100 cm ³ /g Kd: 1600 - 2600 cm ³ /g Time to equilibrium: 3 - 6 hours pH of adsorbent: 6 - 6.6 Temperature: 20 °C Method: OECD 106 * 2000 Data of Imatinib mesylate immobile (soil) Koc: 59000 - 411000 cm ³ /g Kd: 620 - 7800 cm ³ /g Time to equilibrium: 3 - 6 hours pH of adsorbent: 5.7 - 7 Temperature: 20 °C Method: OECD 106 * 2000
PBT assessment	no data available

Safety Data Sheet for Drug Products (US)

Date of issue: 23-MAY-2017

Replaces version of:

GLEEVEC TAB 400MG 30

Other adverse effects no data available

Section 13: Disposal considerations

Disposal Requirements Fill into suitable waste receptacles, seal and label them properly. Incineration in an approved, controlled furnace with combustion gas scrubbing and emission gas control. Local regulations should be adhered to.

Section 14: Transport information

Regulation	IMDG-Code:	ICAO/IATA-DGR:
UN Number	0	0
UN Proper Shipping Name	-	-
Transport Hazard Class(es)		
Transport Label(s)		
Packing group		
Environmental Hazard		
Additional Information		


Special Precaution for User

Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Temperature Conditions for Transport Transport condition: NORMAL: Transport + intermediate storage <=40°C

Section 15: Regulatory information

Chemical characterisation of the substance / preparation:

Chemical Name	Contains:	CAS Number	Picto	Signal Word	Classification
Imatinib mesylate	60 - 62 %	220127-57-1		W	H302, H351, H361d, H373, H401, H411

Regulatory lists of declared components

Contains:

Imatinib mesylate

List type

according to annex I, EC Directive No. 67/548:

Toxic Substances Control Act Not listed or exempted

Remaining components are inert ingredients.

Section 16: Other information

Abbreviations used

H302: Harmful if swallowed.

H351: Suspected of causing cancer.

H361d: Suspected of damaging the unborn child.

H373: May cause damage to organs through prolonged or repeated exposure.

H401: Toxic to aquatic life.(in EU not leading to classification as hazardous)

H411: Toxic to aquatic life with long lasting effects.

Safety Data Sheet for Drug Products (US)



Date of issue: 23-MAY-2017

Replaces version of:

GLEEVEC TAB 400MG 30

Recipient

Product should be stored, handled and used in accordance with good industrial hygiene practices and in conformity with legal regulations. The information contained herein is based on the present state of our knowledge and is intended to describe our products from the point of view of safety requirements. It should therefore not be construed as guaranteeing specific properties.